search
Back to results

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Primary Purpose

Neoplasms

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
GSK6097608
Dostarlimab
GSK4428859A (EOS884448)
Cobolimab
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neoplasms focused on measuring GSK6097608, Dostarlimab, Dose escalation, Pharmacokinetics, Pharmacodynamics, Advanced solid tumors, First-time-in-human, GSK4428859A, EOS884448, Cobolimab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults 18 years of age or older (or >=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, and Arm F-Japan);
  • Female participants of childbearing potential must agree to use a highly effective form of contraception;
  • Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy;
  • Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists;
  • Participants in a PK/PD cohort must provide fresh tumor biopsies.
  • Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1
  • Life expectancy of at least 12 weeks.
  • Adequate organ function as determined by laboratory assessments.
  • Adequate cardiac ejection fraction as measured by echocardiogram.
  • Arm A-Japan, Arm D-Japan, Arm E-Japan, and Arm F-Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese.
  • Arm A-China, Arm B-China, Arm D-China, Arm E-China and Arm F-China only: is of Chinese descent and lives in China.
  • Arm D, Arm E, and Arm F only: has been deemed suitable for assigned treatment based on assessment by the investigator.

Exclusion Criteria:

  • Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter.
  • Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.
  • Toxicity from previous anticancer treatment, including; greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved; or myocarditis of any grade considered related to prior immuno-oncology therapy that led to treatment discontinuation.
  • Known additional malignancy that progressed or required active treatment within the last 2 years.
  • Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years.
  • Concurrent medical condition requiring the use of systemic immunosuppressive treatment.
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment.
  • Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
  • Prolonged QT as measured by electrocardiogram.
  • Allergen desensitization therapy within 4 weeks of starting study intervention.
  • History of hypersensitivity to any of the study interventions or their excipients.
  • History or evidence of significant cardiovascular (CV) risk.
  • Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.
  • History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required steroids, or evidence of active, noninfectious pneumonitis.
  • Pregnant or lactating woman.
  • Receipt of live vaccine within 30 days of the start of study intervention.
  • Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention.
  • Major surgery less than 4 weeks before the first dose of study intervention.
  • Known drug or alcohol abuse.

Sites / Locations

  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting
  • GSK Investigational SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Participants receiving GSK6097608 monotherapy (Arm A)

Participants receiving GSK6097608 plus dostarlimab (Arm B)

Participants receiving dostarlimab monotherapy (Arm D)

Participants receiving dostarlimab plus GSK4428859A (EOS884448) (Arm E)

Participants receiving dostarlimab plus GSK4428859A (EOS884448) plus GSK6097608 (Arm F)

Participants receiving dostarlimab plus cobolimab (Arm G)

Arm Description

Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.

Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.

Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).

Participants will be administered IV infusions of dostarlimab followed by of GSK4428859A (EOS884448), every 3 weeks.

Participants will be administered an IV infusion of dostarlimab followed GSK4428859A (EOS884448) followed by GSK6097608 every 3 weeks.

Participants will be administered an IV infusion of cobolimab followed by dostarlimab

Outcomes

Primary Outcome Measures

Number of participants with dose-limiting toxicities (DLTs)
Number of participants with adverse events (AEs) and serious adverse events (SAEs)

Secondary Outcome Measures

Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings
Number of participants with dose reductions or delay
Number of participants withdrawn due to AEs
Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Arms D, E, F, G: ORR based on modified Response Evaluation Criteria in Solid Tumors (iRECIST)
Arms D, E, F, G: Disease Control Rate (DCR) based on RECIST 1.1
Arms D, E, F, G: DCR based on iRECIST
Arms D, E, F, G: Time to response (TTR) based on RECIST 1.1
Arms D, E, F, G: TTR based on iRECIST
Arms D, E, F, G: Duration of response (DOR) based on RECIST 1.1
Arms D, E, F, G: DOR based on iRECIST
Arms D, E, F, G: Progression-free survival (PFS) based on RECIST 1.1
Arms D, E, F, G: PFS based on iRECIST
Arms A, B, F: Number of participants with positive anti-drug antibodies (ADAs) against GSK6097608
Arms A, B, F: Titers of ADAs against GSK6097608
Arms B, D, E, F, G: Number of participants with positive ADAs against dostarlimab
Arms B, D, E, F, G: Titers of ADAs against dostarlimab
Arms E, F: Number of participants with positive ADAs against GSK4428859A (EOS884448)
Arms E, F: Titers of ADAs against GSK4428859A (EOS884448)
Arm G: Number of participants with positive ADAs against cobolimab
Arm G: Titers of ADAs against cobolimab
Arms A, B, F: Maximum observed concentration (Cmax) for GSK6097608
Arms A, B, F: Minimum observed concentration (Cmin) for GSK6097608
Arms A, B, F: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) for GSK6097608
Arms A, B, F: Area under the plasma concentration-time curve from time zero to time (AUC[0-t]) for GSK6097608
Arms A, B, F: Apparent terminal phase half-life (t1/2) for GSK6097608
Arms B, D, E, F, G: Cmax for dostarlimab
Arms B, D, E, F, G: Cmin for dostarlimab
Arms B, D, E, F, G: AUC(0-infinity) for dostarlimab
Arms B, D, E, F, G: AUC(0-t) for dostarlimab
Arms B, D, E, F, G: t1/2 for dostarlimab
Arms E, F: Cmax for GSK4428859A (EOS884448)
Arms E, F: Cmin for GSK4428859A (EOS884448)
Arms E, F: AUC(0-infinity) for GSK4428859A (EOS884448)
Arms E, F: AUC(0-t) for GSK4428859A (EOS884448)
Arms E, F: t1/2 for GSK4428859A (EOS884448)
Arm G: Cmax for cobolimab
Arm G: Cmin for cobolimab
Arm G: AUC(0-infinity) for cobolimab
Arm G: AUC(0-t) for cobolimab
Arm G: t1/2 for cobolimab

Full Information

First Posted
June 22, 2020
Last Updated
June 22, 2023
Sponsor
GlaxoSmithKline
Collaborators
23andMe, Inc., iTeos Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04446351
Brief Title
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Official Title
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 25, 2020 (Actual)
Primary Completion Date
July 30, 2024 (Anticipated)
Study Completion Date
July 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
Collaborators
23andMe, Inc., iTeos Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy and in combination with GSK6097608 and with GSK4428859A (EOS884448) in Japanese and Chinese participants and dostarlimab will be given in combination with cobolimab in Japanese participants. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as GSK4428859A (EOS884448).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neoplasms
Keywords
GSK6097608, Dostarlimab, Dose escalation, Pharmacokinetics, Pharmacodynamics, Advanced solid tumors, First-time-in-human, GSK4428859A, EOS884448, Cobolimab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Participants will receive treatment in different dose escalation arms of the study.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
184 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Participants receiving GSK6097608 monotherapy (Arm A)
Arm Type
Experimental
Arm Description
Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
Arm Title
Participants receiving GSK6097608 plus dostarlimab (Arm B)
Arm Type
Experimental
Arm Description
Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
Arm Title
Participants receiving dostarlimab monotherapy (Arm D)
Arm Type
Experimental
Arm Description
Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
Arm Title
Participants receiving dostarlimab plus GSK4428859A (EOS884448) (Arm E)
Arm Type
Experimental
Arm Description
Participants will be administered IV infusions of dostarlimab followed by of GSK4428859A (EOS884448), every 3 weeks.
Arm Title
Participants receiving dostarlimab plus GSK4428859A (EOS884448) plus GSK6097608 (Arm F)
Arm Type
Experimental
Arm Description
Participants will be administered an IV infusion of dostarlimab followed GSK4428859A (EOS884448) followed by GSK6097608 every 3 weeks.
Arm Title
Participants receiving dostarlimab plus cobolimab (Arm G)
Arm Type
Experimental
Arm Description
Participants will be administered an IV infusion of cobolimab followed by dostarlimab
Intervention Type
Drug
Intervention Name(s)
GSK6097608
Intervention Description
GSK6097608 will be administered as an IV infusion.
Intervention Type
Drug
Intervention Name(s)
Dostarlimab
Intervention Description
Dostarlimab will be administered as an IV infusion.
Intervention Type
Drug
Intervention Name(s)
GSK4428859A (EOS884448)
Intervention Description
GSK4428859A (EOS884448) will be administered as an IV infusion.
Intervention Type
Drug
Intervention Name(s)
Cobolimab
Intervention Description
Cobolimab will be administered as an IV infusion.
Primary Outcome Measure Information:
Title
Number of participants with dose-limiting toxicities (DLTs)
Time Frame
Up to Day 21
Title
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings
Time Frame
Up to 2 years
Title
Number of participants with dose reductions or delay
Time Frame
Up to 2 years
Title
Number of participants withdrawn due to AEs
Time Frame
Up to 2 years
Title
Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Time Frame
Up to 2 years
Title
Arms D, E, F, G: ORR based on modified Response Evaluation Criteria in Solid Tumors (iRECIST)
Time Frame
Up to 2 years
Title
Arms D, E, F, G: Disease Control Rate (DCR) based on RECIST 1.1
Time Frame
Up to 2 years
Title
Arms D, E, F, G: DCR based on iRECIST
Time Frame
Up to 2 years
Title
Arms D, E, F, G: Time to response (TTR) based on RECIST 1.1
Time Frame
Up to 2 years
Title
Arms D, E, F, G: TTR based on iRECIST
Time Frame
Up to 2 years
Title
Arms D, E, F, G: Duration of response (DOR) based on RECIST 1.1
Time Frame
Up to 2 years
Title
Arms D, E, F, G: DOR based on iRECIST
Time Frame
Up to 2 years
Title
Arms D, E, F, G: Progression-free survival (PFS) based on RECIST 1.1
Time Frame
Up to 2 years
Title
Arms D, E, F, G: PFS based on iRECIST
Time Frame
Up to 2 years
Title
Arms A, B, F: Number of participants with positive anti-drug antibodies (ADAs) against GSK6097608
Time Frame
Up to 2 years
Title
Arms A, B, F: Titers of ADAs against GSK6097608
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: Number of participants with positive ADAs against dostarlimab
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: Titers of ADAs against dostarlimab
Time Frame
Up to 2 years
Title
Arms E, F: Number of participants with positive ADAs against GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arms E, F: Titers of ADAs against GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arm G: Number of participants with positive ADAs against cobolimab
Time Frame
Up to 2 years
Title
Arm G: Titers of ADAs against cobolimab
Time Frame
Up to 2 years
Title
Arms A, B, F: Maximum observed concentration (Cmax) for GSK6097608
Time Frame
Up to 2 years
Title
Arms A, B, F: Minimum observed concentration (Cmin) for GSK6097608
Time Frame
Up to 2 years
Title
Arms A, B, F: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) for GSK6097608
Time Frame
Up to 2 years
Title
Arms A, B, F: Area under the plasma concentration-time curve from time zero to time (AUC[0-t]) for GSK6097608
Time Frame
Up to 2 years
Title
Arms A, B, F: Apparent terminal phase half-life (t1/2) for GSK6097608
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: Cmax for dostarlimab
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: Cmin for dostarlimab
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: AUC(0-infinity) for dostarlimab
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: AUC(0-t) for dostarlimab
Time Frame
Up to 2 years
Title
Arms B, D, E, F, G: t1/2 for dostarlimab
Time Frame
Up to 2 years
Title
Arms E, F: Cmax for GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arms E, F: Cmin for GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arms E, F: AUC(0-infinity) for GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arms E, F: AUC(0-t) for GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arms E, F: t1/2 for GSK4428859A (EOS884448)
Time Frame
Up to 2 years
Title
Arm G: Cmax for cobolimab
Time Frame
Up to 2 years
Title
Arm G: Cmin for cobolimab
Time Frame
Up to 2 years
Title
Arm G: AUC(0-infinity) for cobolimab
Time Frame
Up to 2 years
Title
Arm G: AUC(0-t) for cobolimab
Time Frame
Up to 2 years
Title
Arm G: t1/2 for cobolimab
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults 18 years of age or older (or >=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan); Female participants of childbearing potential must agree to use a highly effective form of contraception; Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy; Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists; Participants in a PK/PD cohort must provide fresh tumor biopsies. Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1 Life expectancy of at least 12 weeks. Adequate organ function as determined by laboratory assessments. Adequate cardiac ejection fraction as measured by echocardiogram. Arm A-Japan, Arm D-Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese. Arm A-China, Arm B-China, Arm D-China, Arm E-China and Arm F-China only: is of Chinese descent and lives in China. Arm D, Arm E, Arm F, and Arm G only: has been deemed suitable for assigned treatment based on assessment by the investigator. Exclusion Criteria: Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter. Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation. Toxicity from previous anticancer treatment, including; greater than or equal to (>=) Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved; or history of myocarditis of any grade during a previous treatment with immunotherapy. Known additional malignancy that progressed or required active treatment within the last 2 years. Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. Concurrent medical condition requiring the use of systemic immunosuppressive treatment. Cirrhosis or current unstable liver or biliary disease per investigator assessment. Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) Prolonged QT as measured by electrocardiogram. Allergen desensitization therapy within 4 weeks of starting study intervention. History of hypersensitivity to any of the study interventions or their excipients. History or evidence of significant cardiovascular (CV) risk. Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions. History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required steroids, or evidence of active, noninfectious pneumonitis. Pregnant or lactating woman. Receipt of live vaccine within 30 days of the start of study intervention. Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention. Major surgery less than 4 weeks before the first dose of study intervention. Known drug or alcohol abuse.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name or Official Title & Degree
EU GSK Clinical Trials Call Center
Phone
+44 (0) 20 89904466
Email
GSKClinicalSupportHD@gsk.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Omid Hamid
Facility Name
GSK Investigational Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Frank Stephen Hodi
Facility Name
GSK Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Reva Elaine Schneider
Facility Name
GSK Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Jordi Rodón Ahnert
Facility Name
GSK Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Drew W Rasco
Facility Name
GSK Investigational Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Scott A Laurie
Facility Name
GSK Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1Z5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Lillian Siu
Facility Name
GSK investigational Site
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Center
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Yoshitake Zenke
Facility Name
GSK Investigational Site
City
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Noboru Yamamoto
Facility Name
GSK Investigational Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Dong Wan Kim
Facility Name
GSK Investigational Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
US GSK Clinical Trials Call Center
Phone
877-379-3718
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
EU GSK Clinical Trials Call Centre
Phone
+44 (0) 20 8990 4466
Email
GSKClinicalSupportHD@gsk.com
First Name & Middle Initial & Last Name & Degree
Myung-Ju Ahn

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months
IPD Sharing URL
https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Learn more about this trial

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

We'll reach out to this number within 24 hrs